Sensex, Nifty trade in negative terrain; consumer durables shares tumble
Consumer durables shares declined after witnessing buying demand in the past four trading sessions.
At 14:25 IST, the barometer index, the S&P BSE Sensex declined 500.66 points or 0.61% to 81,764.54. The Nifty 50 index slipped 137.15 points or 0.55% to 24,974.20.
In the broader market The S&P BSE Mid-Cap index shed 0.51% and the S&P BSE Small-Cap index declined 0.61%.
The market breadth was weak. On the BSE, 1,526 shares rose and 2,443 shares fell. A total of 178 shares were unchanged.
Buzzing Index:
The Nifty Consumer Durables declined 0.84% to 38,671.95. The index increased 2.36% in the past four trading sessions.
PG Electroplast (down 2.14%), Blue Star (down 2.01%), Cera Sanitaryware (down 1.69%), Crompton Greaves Consumer Electricals (down 1.47%), Kalyan Jewellers India (down 1.42%), Century Plyboards (India) (down 0.92%), Voltas (down 0.86%), Havells India (down 0.85%), Bata India (down 0.77%) and Titan Company (down 0.74%) declined.
Numbers to Track:
The yield on India's 10-year benchmark federal paper declined 0.06% to 6298 compared with previous close of 6.303.
In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 86.1700 compared with its close of 86.1200 during the previous trading session.
MCX Gold futures for 5 August 2025 settlement rose 0.40% to Rs 97,865
The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.33% to 98.32.
The United States 10-year bond yield fell 0.49% to 4.442.
In the commodities market, Brent crude for September 2025 settlement advanced 22 cents or 0.32% to $69.74 a barrel.
Stocks in Spotlight:
Garuda Construction and Engineering zoomed 16.87% after the company reported a consolidated net profit of Rs 27.99 crore in Q1 FY26, which is nearly 3 times the PAT of Rs 8.64 crore recorded in Q1 FY25. Revenue from operations for the first quarter aggregated to Rs 125.15 crore, up 3.6 times on year-on-year (YoY) basis. Revenue in the same period last year was Rs 35.12 crore.
LTIMindtree declined 1.20%. The company reported a 11.13% jump in consolidated net profit to Rs 1,254.10 crore on 0.71% increase in revenue from operations to Rs 9,840.60 crore in Q1 FY26 over Q4 FY25.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
24 minutes ago
- India.com
India Announced Big Move As Pakistan Kept Watching: Sawalkot Hydropower Project On Chenab To Resume After 40 Years
Srinagar: The Sawalkot hydropower project lay buried in bureaucratic delays and geopolitical tensions for decades. Now, for the first time in 40 years, India has moved to bring the stalled dream back to life. Days after suspending the Indus Waters Treaty with Pakistan following the Pahalgam terror attack, New Delhi has given the green signal to resume work on the long-pending project along the Chenab river. The decision marks a strategic shift. The National Hydroelectric Power Corporation (NHPC) floated international tenders on Wednesday for design and engineering work on the project. Located near the village of Sidhra in Jammu and Kashmir's Ramban district, Sawalkot is designed to generate 1,856 megawatts of power. It could eventually become one of the biggest infrastructure projects in the region. The deadline for tender submission is set for September 10. Old Blueprint, New Push The Sawalkot project was conceptualised in the 1980s but never got off the ground. It ran into hurdles almost immediately. Pakistan raised repeated objections under the Indus Waters Treaty, arguing that such projects on western rivers violated the spirit of the agreement. While maintaining it was within its rights, India paused the process several times. There were domestic challenges too such as compensation for families in 13 affected villages, shifting a transit camp of the Army and getting forest clearance under environmental rules. All of this stalled any real progress. Now, many of those hurdles appear to have been cleared. Earlier this month, the Forest Advisory Committee gave in-principle approval to divert around 847 hectares of forest land for the project. The government has also waived the water usage fee for the NHPC, offering it a financial cushion. More Than a Dam The Centre sees Sawalkot as a national-level infrastructure need that is important not only for Jammu & Kashmir, but also for the wider push towards energy independence. It is a run-of-the-river project, meaning it will not require large reservoirs but will harness the natural flow of the Chenab to generate electricity. The estimated cost of the project is over Rs 22,700 crore, and it will be developed in two phases. A Treaty Under Stress When the Indus Waters Treaty was signed in 1960, India got control over three eastern rivers, Beas, Ravi and Sutlej. Pakistan received rights over the western rivers – Indus, Jhelum and Chenab. The treaty allowed India limited use of water from the western rivers for non-consumptive purposes, including hydropower. For years, India respected those limits. But with Pakistan using the treaty to repeatedly block projects, New Delhi's patience has thinned. By moving forward with Sawalkot now, India appears to be asserting its rights more strongly. A Political Legacy Revisited J&K Chief Minister Omar Abdullah, who also holds the power portfolio in the current administration, said the revival of Sawalkot was overdue. 'This project is very important. I had tried to restart it during my last tenure, but many roadblocks came in the way,' he said. He highlighted that the original work was stopped in 1996. His father and former Chief Minister Dr. Farooq Abdullah, had tried to restart it with the help of a Norwegian consortium, but even that attempt failed. Later, under Mufti Mohammad Sayeed's leadership, the project was shelved entirely. Now, nearly three decades later, the wheels are turning again. The Sawalkot dam might not just light up homes. It might light up a whole new phase in India's water diplomacy.
Time of India
42 minutes ago
- Time of India
BJP says only thing dead is Rahul's political legacy
Rahul Gandhi (File photo) NEW DELHI: BJP on Thursday said Rahul Gandhi 's latest tirade on the Indian economy by endorsing the "dead economy" jibe of US President Donald Trump has proved that the Congress leader is "delusional, ignorant of facts and deeply frustrated". The party also took a swipe at Rahul, citing his affidavit from the 2024 Lok Sabha elections as per which he invested Rs 8 crore in the same "dead economy". "The latest tirade by Rahul Gandhi on the Indian economy has proved once again that not only he is delusional and ignorant of facts but also deeply frustrated. Parroting imported narratives to show India in bad light and posing like an expert may serve his politics but will do little to establish him as a sensible politician," Union minister Dharmendra Pradhan said on X. He said Rahul should come out of his fantasy world, else, the only thing that will be dead and destroyed is the little ground that Congress is holding. The party also questioned that if " demonetisation and a flawed GST" killed the economy, then how come India became the world's fastest-growing major economy, with nominal GDP tripling from 2014-15 to 2024-25. BJP's IT department head Amit Malviya on X said that Rahul has "hit a new low by echoing the 'dead economy' jibe - a shameful insult to the aspirations, achievements, and well-being of the Indian people." "But let's be honest -- the only thing truly 'dead' here is Rahul Gandhi's own political credibility and legacy," he added. The BJP leaders reacted after the leader of opposition Rahul Gandhi said that everyone except Prime Minister Narendra Modi and finance minister Nirmala Sitharaman knows that the Indian economy is "dead". BJP MP Anurag Thakur said making anti-India statements has become Rahul's "mentality". "Whenever anyone makes an anti-India statement in the world, he grabs it," he said.
Time of India
an hour ago
- Time of India
Amid Trump tariff fears, Aurobindo strikes biggest deal; To acquire Lannett for Rs 2185 crore
Hyderabad: Amid rising fears of US President Donald Trump imposing tariffs on Indian pharma imports, Aurobindo Pharma is making its largest acquisition with a 100% stake in Lannett Company from US-based complex generics manufacturer Lannett Seller Holdco Inc for a total enterprise value of $250 million (approx. 2,185 crore) on a cash-free, debt-free basis. The acquisition, to be done through Aurobindo's wholly-owned US subsidiary Aurobindo Pharma USA Inc, will enable the company to expand its manufacturing footprint in the US, Aurobindo Pharma said in a regulatory filing. The Hyderabad-based company said the transaction aligns with its strategic objective to expand its US manufacturing footprint. Lannett has a 4.24 lakh sq ft cGMP (current good manufacturing practices) facility at Seymour in Indiana with a capacity to make around 3.6 billion tablets per annum. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad The plant has the capability to manufacture not just tablets but multiple dosage forms, including capsules, liquids, and powders. Aurobindo said Lannett's US-based facility has significant excess capacity and offers potential for further expansion. Lannett's plant has a strong regulatory and DEA (Drug Enforcement Administration) compliance track record and has built strong expertise in non-opioid controlled substances, mainly in ADHD (attention-deficit, hyperactivity disorder) therapeutics, as well as generic liquids. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Gold Is Surging in 2025 — Smart Traders Are Already In IC Markets Learn More Undo Apart from giving a manufacturing facility in the US, the deal will also give Aurobindo access to a complementary portfolio of profitable products as well as a growing contract development and manufacturing organisation business, it added. "The acquired product portfolio is primarily focused on non-opioid controlled substances, particularly in ADHD therapeutics in which Aurobindo currently has a limited presence. This acquisition strengthens Aurobindo's ability to serve the US generics space and provides strategic diversification into a specialised high-value therapeutic category," Aurobindo Pharma said. The transaction is expected to be completed in 8-12 months and is subject to US Federal Trade Commission approval in addition to other statutory and govt approvals. Though Aurobindo is acquiring Lannett Company Inc, the company will undergo a re-organisation to become Lannett Company LLC before Aurobindo acquires it. Lannett Company clocked a turnover of $306 million (approx. Rs 2674 crore) in the financial year 2024-25. The Lannett acquisition is Aurobindo Pharma's largest buy after its plan to acquire Sandoz's US dermatology and generic oral solids businesses for $1 billion in 2018 fizzled out because they could not secure approval from the US FTC in a timely manner.
